Walker Justin A, Althausen Peter L
Reno Orthopaedic Clinic, Reno, NV.
J Orthop Trauma. 2016 Dec;30 Suppl 5:S27-S31. doi: 10.1097/BOT.0000000000000722.
To determine the role of generic orthopaedic trauma implants in the current orthopaedic trauma market, as perceived by OTA members, and investigate potential hurdles to the use of generic implants and other cost-containment measures.
Survey study.
Not applicable.
All active OTA members with valid e-mail addresses were invited to participate.
Participants completed a brief online survey with questions regarding participation in cost-containment and incentive programs, industry relationships, generic implant use, and the role of surgeons in cost containment.
Survey data.
Participation in cost-containment programs (comanagement agreements, bundled payment for care improvement, and gainsharing) was found to be very low among participants (17%, 36.5%, 17%, respectively). Industry sales representatives were present in a majority of participants' cases (76.9%) the majority of time, but relatively a few surgeons (21.2%) felt their presence was necessary. Most surgeons were aware of the availability of generic implants (72.6%), but a few had adopted the use of such implants (25.5%), despite 50/52 (96.2%) prescribing generic drugs and 45/52 (86.5%) using generic products in their own households.
Most participants agreed that generic orthopaedic implants have a role in cost containment, but a few have adopted these implants. The presence of sales representatives does not seem to be necessary for most surgeons, and minimizing or eliminating their presence may result in substantial savings for health care institutions. Increased education and the use of financial incentive programs may encourage improved surgeon participation in cost containment and adoption of generic implants and may help reduce health care spending.
Level 4. See Instructions for Authors for a complete description of levels of evidence.
确定OTA成员所认为的通用骨科创伤植入物在当前骨科创伤市场中的作用，并调查使用通用植入物及其他成本控制措施的潜在障碍。
调查研究。
不适用。
邀请所有拥有有效电子邮件地址的活跃OTA成员参与。
参与者完成一份简短的在线调查问卷，问题涉及参与成本控制和激励计划、行业关系、通用植入物的使用以及外科医生在成本控制中的作用。
调查数据。
发现参与者中参与成本控制计划（共同管理协议、改善护理的捆绑支付和收益共享）的比例非常低（分别为17%、36.5%、17%）。大多数参与者（76.9%）的病例中大部分时间都有行业销售代表在场，但相对较少的外科医生（21.2%）认为他们的在场是必要的。大多数外科医生知道有通用植入物（72.6%），但只有少数人采用了此类植入物（25.5%），尽管52人中的50人（96.2%）在开通用药物，52人中的45人（86.5%）在自己家中使用通用产品。
大多数参与者同意通用骨科植入物在成本控制中发挥作用，但只有少数人采用了这些植入物。对大多数外科医生来说，销售代表的在场似乎并非必要，减少或消除他们的在场可能会为医疗机构节省大量资金。加强教育和使用财务激励计划可能会鼓励外科医生更多地参与成本控制并采用通用植入物，有助于减少医疗保健支出。
4级。有关证据水平的完整描述，请参阅《作者须知》。
